

Capstone Therapeutics Corp.  
Form 8-K  
February 03, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report: February 3, 2016 (Date of earliest event reported)

**CAPSTONE THERAPEUTICS CORP.**

(Exact name of registrant as specified in its charter)

|  |                          |   |
|--|--------------------------|---|
| Delaware                                       | 000-21214                | 86-0585310                              |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

|  |            |
|--|------------|
| 1275 West Washington Street, Suite 104, Tempe, Arizona | 85281      |
| (Address of principal executive offices)               | (Zip Code) |

Registrant's telephone number, including area code:  
(602) 286-5520

Edgar Filing: Capstone Therapeutics Corp. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 8 – Other Events**

**Item 8.01 Other Events.**

On February 3, 2016, Capstone Therapeutics Corp. (OTCQB: CAPS) and its joint venture affiliate, LipimetiX Development, Inc., entered into a material transfer agreement with a leading pharmaceutical company pursuant to which LipimetiX will provide samples of AEM-28-14 for preclinical evaluation. AEM-28-14 is a patented, synthetic peptide for which LipimetiX holds an exclusive license and which is the joint venture's principal drug candidate.

No license, partnering or other similar arrangements have been entered into in connection with this material transfer agreement, and there is no assurance that any such arrangement will be entered into in the future, whether in respect of all or any portion of the potential indications for which AEM-28-14 might have therapeutic value.

The development of drugs for human use is subject to many significant risks and uncertainties, including those described under "Risk Factors" in Capstone's Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 16, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 3, 2016 CAPSTONE THERAPEUTICS CORP.

/s/ John M. Holliman, III  
John M. Holliman, III  
Executive Chairman and CEO